ConferenceThe Journal of Immunology · August 1, 2026
AbstractIntroductionImmunotherapy has yet to show efficacy in glioblastoma (GBM). To enhance immune priming, the ETAPA phase 1 ...
Full textCite
ConferenceCancer Research · April 3, 2026
AbstractIntroduction/Rationale:Immunotherapy has yet to yield benefit in glioblastoma (GBM), in part due to inadequate T-cell p ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractBACKGROUNDWhen administered via CED in glioma models, D2C7-IT, an antibody toxin conjugate, combined with an anti-mouse ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractBACKGROUNDLerapolturev is a modified, non-pathogenic version of the Sabin⢠type 1 poliovirus vaccine that infects myelo ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractThe introduction of mutant IDH inhibitors (mIDHi) has transformed the treatment landscape for patients with low-grade gliomas (LGG). However, optimal strategies for tumor control following progres ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractSeizures are a common and debilitating complication of primary brain tumors. Nearly 75% of low-grade and 25% of high-grade glioma patients experience seizures. Levetiracetam (LEV) is frequently us ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractBACKGROUNDFibroblast growth factor receptor (FGFR) alterations are a potentially actionable target in various cancers, ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2025
AbstractBACKGROUNDThe TMD is a surgically implanted catheter system that remains in place after tumor resection. The TMD is not ...
Full textCite
ConferenceNeuro-Oncology · October 3, 2025
AbstractBACKGROUNDThe P30-EPS vaccine is a novel multi-epitope peptide immunotherapy targeting class I HLA-A2 epitopes of tumor-associ ...
Full textCite
ConferenceCancer Research · April 25, 2025
AbstractWe developed a novel peptide-based vaccine, P30-EPS, which combines the universal class II-binding P30 epitope derived from tetanus toxoid with HLA-A2:01 class I peptides from tumor-associated antige ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractBACKGROUNDThe combination of D2C7-IT, an antibody toxin conjugate, and anti-mouseCD40 via CED generates robust antitumor immun ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractIsocitrate dehydrogenase 1 (IDH1) inhibitors are transforming the treatment of patients with non-enhancing IDH1 mutant gliomas that have only undergone surgical resection. Questions remain on the uti ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractIvosidenib offers a novel targeted therapy for non-enhancing IDH1 mutated gliomas following initial resection. Potential effects of IDH inhibitors on enhancing disease in clinical settings are not we ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractBACKGROUNDIsocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH- ...
Full textCite
ConferenceNeuro-Oncology · November 11, 2024
AbstractBACKGROUNDMagnetic Resonance Imaging (MRI) response assessment is essential in isocitrate dehydrogenase (IDH)-mutant gliomas a ...
Full textCite
ConferenceNeuro-Oncology · October 17, 2024
AbstractBACKGROUNDPhase 1 and 2 clinical trials of a single intratumoral injection of LERA (previously PVSRIPO) via CED into enhancing ...
Full textCite
ConferenceCancer Research · April 4, 2023
AbstractGlioblastoma (GBM), the most common primary malignant brain tumor in adults, is an incurable disease that has an inevitable tendency to recur following standard of care surgery, radiotherapy, and tem ...
Full textCite
ConferenceNEURO-ONCOLOGY · November 14, 2022
BACKGROUND
COVID-19 radically changed neuro-oncology care. In this retrospective study, we examine the impact of COVID-19 infection on neuro-oncological care and clinical outcomes in two geographically separate populations.
METHODS
Descriptive statistics ...
Full textLink to itemCite
ConferenceJOURNAL OF CLINICAL ONCOLOGY · 2022
Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ...
Full textLink to itemCite
ConferenceJOURNAL OF CLINICAL ONCOLOGY · 2022
Background: High-grade gliomas (HGGs) are immunologically âcoldâ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ...
Full textLink to itemCite
ConferenceNeuro-Oncology · November 12, 2021
AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ...
Full textOpen AccessLink to itemCite
ConferenceNeuro-Oncology · November 12, 2021
AbstractIsocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for t ...
Full textOpen AccessLink to itemCite
ConferenceNeuro-Oncology · November 12, 2021
AbstractINTRODUCTIONVaccination with dendritic cells (DCs) fares poorly in primary and recurrent glioblastoma (GBM). Moreover, GBM vac ...
Full textOpen AccessLink to itemCite
ConferenceNeuro-Oncology · November 12, 2021
AbstractBACKGROUNDPVSRIPO is a live-attenuated recombinant rhino:poliovirus that mediates antitumor efficacy by engaging antitumor imm ...
Full textCite
ConferenceCancer Research · July 1, 2021
AbstractBackground: The prognosis for patients (pts) with recurrent (r) glioblastoma (GBM) is poor, with no highly effective approved therapies. Treatment failure may result from poor penetration of drugs th ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2021
TPS2065
Background: The prognosis for patients (pts) with recurrent (r) glioblastoma (GBM) is poor, with no highly effective approved therapies. Treatment failure may result from poor penetrat ...
Full textCite
ConferenceNEURO-ONCOLOGY · 2021
Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for the gliomagenesis associated with these tumors and the pro ...
Full textLink to itemCite
ConferenceNEURO-ONCOLOGY · 2020
Abstract
INTRODUCTION
We previously reported to SNO, high levels of psychosocial distress in adult patients with primary brain tumors (PBTs), particularly during the first 6 months following diagnosis. The purpose of this follow-up study was to identify pa ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
2060
Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ...
Full textLink to itemCite
ConferenceNeurology · April 9, 2018
158
Objective: The purpose of this study is to analyze adult patients with pilocytic astrocytomas and to identify factors associated with recurrence and survival.
Background: Pilocytic astrocytomas (WHO grade I) represent the most common central nervous s ...
Link to itemCite
ConferenceNeuro-Oncology · November 1, 2017
RATE-36
INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkinâs lymphoma that involves the brain, spinal cord or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~3% of all primary centr ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e21636 Background: At diagnosis, GBM patients face the immediate challenge of significant morbidity and mortality. In this population, we have shown that better exercise behavior is an independent prognostic factor for improved s ...
Full textLink to itemCite
ConferenceNeurology · April 27, 2017
Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM.
Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ...
Link to itemCite
ConferenceSupport Care Cancer · October 2016
BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
Background: Overall survival of patients with glioblastoma (GBM) remains dismal with range from 12-14 months. In addition to the oncologic burden that these patients face during the disease trajectory, there are demonstrable neurologic and cognitive challe ...
Full textLink to itemCite
ConferenceCancer · December 1, 2013
BACKGROUND: The incidence and spectrum of acute toxicities related to the use of bevacizumab (BVZ)-containing regimens in children are largely unknown. This report describes the adverse events in a recently completed large phase 2 trial of BVZ plus irinote ...
Full textLink to itemCite
ConferenceCancer Research · April 15, 2013
AbstractINTRODUCTION: INC280 is an oral, highly selective c-Met receptor tyrosine kinase inhibitor. The hepatocyte growth factor (HGF)-c-Met pathway is one of the most frequently dysregulated pathways in hum ...
Full textCite
ConferenceCancer · April 2003
AbstractBACKGROUNDIt is well recognized that many patients with head and neck carcinoma have problems with food intake and malnutrition. The objective of the current study was to determine ...
Full textCite